A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma

Trial Profile

A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma

Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2018

At a glance

  • Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Tocagen
  • Most Recent Events

    • 21 May 2018 Status changed from active, no longer recruiting to completed.
    • 17 Oct 2017 According to a Tocagen media release, Updated Durable Response Data from this study will be presented at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 23 Feb 2017 According to a Tocagen media release, the U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of patients with recurrent high grade glioma (HGG). Data from this study supported the application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top